Fresenius Kabi nutrition drug approved for babies

LAKE ZURICH - Fresenius Kabi said it has been granted an expanded use of a nutritional drug, which the Food and Drug Administration says can now be prescribed for infants.

"The FDA approval of SMOFlipid for pediatric patients represents an important expansion of our parenteral nutrition portfolio and our continued commitment to providing innovative nutrition products to our clinical partners and the patients they serve," said Gordon Sacks, senior director Medical Affairs, Fresenius Kabi USA.

Parenteral nutrition is the intravenous administration of amino acids (protein), carbohydrates (dextrose), lipids (fats), electrolytes, vitamins and other trace elements for patients who cannot digest or absorb sufficient nutrition via the gastrointestinal tract. It can be provided in the hospital, in long-term care facilities, or at home.